Solid Biosciences (SLDB) Equity Average (2018 - 2024)
Historic Equity Average for Solid Biosciences (SLDB) over the last 7 years, with Q3 2024 value amounting to $180.1 million.
- Solid Biosciences' Equity Average rose 1693.6% to $180.1 million in Q3 2024 from the same period last year, while for Sep 2024 it was $180.1 million, marking a year-over-year increase of 1693.6%. This contributed to the annual value of $169.1 million for FY2023, which is 1946.52% down from last year.
- Per Solid Biosciences' latest filing, its Equity Average stood at $180.1 million for Q3 2024, which was up 1693.6% from $202.0 million recorded in Q2 2024.
- In the past 5 years, Solid Biosciences' Equity Average registered a high of $245.5 million during Q2 2021, and its lowest value of $31.5 million during Q3 2020.
- Its 5-year average for Equity Average is $159.1 million, with a median of $173.9 million in 2022.
- As far as peak fluctuations go, Solid Biosciences' Equity Average tumbled by 6597.99% in 2020, and later skyrocketed by 63287.53% in 2021.
- Quarter analysis of 5 years shows Solid Biosciences' Equity Average stood at $77.2 million in 2020, then soared by 179.67% to $215.8 million in 2021, then decreased by 17.76% to $177.5 million in 2022, then dropped by 23.69% to $135.4 million in 2023, then surged by 33.02% to $180.1 million in 2024.
- Its Equity Average was $180.1 million in Q3 2024, compared to $202.0 million in Q2 2024 and $168.6 million in Q1 2024.